GlassScriptPhysician profile
Allyx Bowthorpe
NPI 1033509989
$2,283.43
in general payments reported to CMS, 2019-2025
24 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $436 · 2022: $394 · 2023: $364 · 2024: $676 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.12 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $414.85 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $307.44 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $196.98 | 2021-2025 | Libtayo, Dupixent |
| Allergan, INC. | $191.02 | 2021-2022 | |
| Dermavant Sciences, INC. | $161.79 | 2024 | Vtama |
| Leo Pharma INC. | $143.06 | 2022-2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $105.25 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $96.75 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $95.57 | 2021-2025 | Ebglyss, Taltz |
| E.R. Squibb & Sons, L.L.C. | $89.69 | 2022-2024 | Sotyktu |
| Incyte Corporation | $78.33 | 2021-2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.12 | 2023-2024 | Spevigo |
| Ucb, INC. | $65.52 | 2024 | Bimzelx |
| Pfizer INC. | $37.13 | 2021 | |
| Dermira, INC. | $32.67 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $32.04 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $29.59 | 2024-2025 | |
| Almirall LLC | $22.98 | 2025 | Seysara |
| Sanofi-Aventis U.S. LLC | $21.35 | 2021 | |
| Amgen INC. | $19.41 | 2022 | |
| Genzyme Corporation | $18.21 | 2021 | |
| Organon LLC | $17.79 | 2025 | Nexplanon |
| Janssen Scientific Affairs, LLC | $15.14 | 2024 | Tremfya |
| Epi Health, LLC | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyx Bowthorpe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.